Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study

China Omalizumab Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number100469
JournalWorld Allergy Organization Journal
Volume13
Issue number12
DOIs
StatePublished - Dec 2020
Externally publishedYes

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Keywords

  • Allergic
  • Asthma
  • China
  • Eosinophils
  • Immunoglobulin E
  • Omalizumab

Cite this